Consultant Physician

Recommendations

Info

Template care vs. personalized medicine Template care is increasingly at odds with the emergence of personalized medicine, a new discipline driven by the exploding knowledge of the human genome that guides treatment tailored to the individual patient. And this is what today's medical students will be practicing
Delaying the Onset of Type 2 Diabetes Among those at high risk, the proposed 3- step approach was to A) identify those who may be at higher risk, B) measure the risk, and C) intervene to delay/prevent the onset of type 2 diabetes using predominantly health behaviour strategies to affect the modifiable risk factors for type 2 diabetes.
Page 1 and 2:
Credibility and Evidence Based Natu
Page 3 and 4:
Aim of presentation • How far the
Page 5 and 6:
The relationship between exposure t
Page 7 and 8:
Conflict of interest (COI) The trad
Page 9 and 10:
Candidate List of Categories of Fin
Page 11 and 12:
Actual or reasonably perceived conf
Page 13 and 14:
Physician relationships with the in
Page 15 and 16:
Physician Relationships With The In
Page 17 and 18:
Physician Relationships With The In
Page 19 and 20:
Concerns Regarding Physician Relati
Page 21 and 22:
Ethics And Compliance Payments to
Page 23 and 24:
Ethics And Compliance Biopharmaceut
Page 25 and 26:
Guidelines For Physician-Pharmaceut
Page 27 and 28:
Financial Conflicts of Interest Che
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Drug surveillance and a real world
Page 35 and 36:
Systems for assessment of postmarke
Page 37 and 38:
Systems for assessment of postmarke
Page 39 and 40:
Exposures to information from pharm
Page 41 and 42:
Why we as prescribers still meet ph
Page 43 and 44:
This is how each of the companies l
Page 45 and 46:
After two decades of decimation, on
Page 47 and 48:
Incretin Drugs Contribute Heavily t
Page 49 and 50:
A Clouded Future For Big Pharma's B
Page 51 and 52:
The largest health fraud settlement
Page 53 and 54:
Use of drugs and its budgetary impl
Page 55 and 56:
Key functions of drug regulatory ag
Page 57 and 58: Relationships Between Authors of Cl
Page 59 and 60: Conflicts (Dualities) of interest i
Page 61 and 62: Conflicts (Dualities) of interest a
Page 63 and 64: Cross-sectional survey of 192 autho
Page 65 and 66: Clinical practice guidelines for di
Page 67 and 68: Hierarchy of evidence-based medicin
Page 69 and 70: Criteria for assigning levels of ev
Page 71 and 72: Criteria for assigning grades of re
Page 73 and 74: Criteria for assigning levels of ev
Page 75 and 76: Meta-analysis may not consider COI
Page 77 and 78: Financial disclosures in RCT’s* 5
Page 79 and 80: Large trials that compared clinical
Page 81 and 82: HBA1C targets suggested by differen
Page 83 and 84: The goal for A1c may not be safely
Page 85 and 86: A Patient- Centered Approach to Typ
Page 87 and 88: According to subset analyses from a
Page 89 and 90: Approach to management of hyperglyc
Page 91 and 92: VA/DoD Clinical Practice Guideline
Page 93 and 94: What is Algorithm (in guidelines)?
Page 95 and 96: Types of medical practice setting
Page 97 and 98: In summary why we need clinical pra
Page 99 and 100: Dissemination and implementation an
Page 101 and 102: Clinical Practice Guidelines (CPGs)
Page 107: Personalized medicine Using a pers
Page 111 and 112: Intervention studies on the prevent
Page 113 and 114: Management of hyperglycaemia in typ
Page 115 and 116: General recommendations for managem
Page 117 and 118: ADA-EASD Position Statement: Manage
Page 119 and 120: Management of Hyperglycemia in T2DM
Page 121 and 122: AACE/ACE* Diabetes Algorithm For Gl
Page 123 and 124: Dr. Alashbal’ s observation regar
Page 133 and 134: Management of hyperglycemia in type
Page 135 and 136: Relevant comments on ADA/EASD algor
Page 144 and 145: Sequential insulin strategies in ty
Page 146 and 147: ADA/EASD position statement 2012 In
Page 148 and 149: ADA/EASD position statement 2012 L
Page 150 and 151: Individualization of therapy ADA/EA
Page 152 and 153: NICE Type 2 diabetes algorithm for
Page 154 and 155: Relevant comments on NICE algorithm
Page 156 and 157: Relevant comments on SIGN algorithm
Page 158 and 159:
Relevant comments on DoD/VA algorit
Page 160 and 161:
Comparison of the ADA/EASD algorith
Page 162 and 163:
Comparison of the ADA/EASD algorith
Page 164 and 165:
Pharmacotherapy of Type 2 Diabetes
Page 166 and 167:
Maximum blood glucose lowering effe
Page 168 and 169:
Dose-response relationships of sulp
Page 170 and 171:
Hazard ratios (95% CI) for differen
Page 172 and 173:
"metformin, sulfonylureas, • •
Page 174 and 175:
Efficacy of monotherapy Drug Thiazo
Page 176 and 177:
Insulin is the most effective diabe
Page 178 and 179:
Burdens of insulin therapy as a fir
Page 180 and 181:
Why health care providers and patie
Page 182 and 183:
ADA-EASD Position Statement: Manage
Page 184 and 185:
The maximum period after which we m
Page 186 and 187:
Doctor, patient, and system barrier
Page 188 and 189:
Painful truth and big question why
Page 190 and 191:
Report of Institute for Quality and
Page 192 and 193:
Report of Institute for Quality and
Page 194 and 195:
Insulin glargine vs. NPH insulin In
Page 196 and 197:
Safety of Incretin-Based Therapies
Page 198 and 199:
The use of incretin-based glucose-l
Page 200 and 201:
Dr. Alashbal’ s observation regar
Page 202 and 203:
Conclusions The pendulum is swingin
Page 204 and 205:
Suggested seven deadly sins of drug
Page 206 and 207:
Never be And the first, this sin is
Page 208:
hank you Dr. Abdulameer Abdullah Al
show all

Consultant Physician

Create successful ePaper yourself

Delete template?

Save as template?